Observations placeholder
Temsirolimus and Torisel
Identifier
017731
Type of Spiritual Experience
Background
A description of the experience
Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), approved by the U.S. Food and Drug Administration (FDA) in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus and is sold as Torisel.
On Jan, 11, 2017 2,792 people reported to have side effects when taking Torisel. Among them, 18 people (0.64%) have Hallucination
Time on Torisel when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 40.00% | 60.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Age of people who have Hallucination when taking Torisel :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 28.57% | 71.43% |